• LAST PRICE
    3.3677
  • TODAY'S CHANGE (%)
    Trending Up0.0877 (2.6738%)
  • Bid / Lots
    3.2600/ 1
  • Ask / Lots
    3.3800/ 2
  • Open / Previous Close
    3.2300 / 3.2800
  • Day Range
    Low 3.2300
    High 3.3825
  • 52 Week Range
    Low 2.7400
    High 11.9900
  • Volume
    6,149
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 3.28
TimeVolumeLTRN
09:32 ET3803.23
09:33 ET1003.28
09:35 ET10223.3
09:37 ET1763.3212
09:53 ET1003.3825
10:04 ET1003.33
10:11 ET1003.37
10:13 ET1503.3688
10:15 ET2003.3701
10:24 ET1003.3
10:33 ET3003.324
10:38 ET1003.32
10:49 ET2003.301
10:54 ET1003.3
11:12 ET13023.27
11:20 ET1523.3677
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLTRN
Lantern Pharma Inc
35.3M
-2.0x
---
United StatesHSTC
HST Global Inc
35.7M
-43.6x
---
United StatesAEON
Aeon Biopharma Inc
34.7M
-0.1x
---
United StatesNXTC
NextCure Inc
36.6M
-0.6x
---
United StatesRVPH
Reviva Pharmaceuticals Holdings, Inc.
33.4M
-0.8x
---
United StatesPASG
Passage Bio Inc
37.3M
-0.5x
---
As of 2024-11-05

Company Information

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Contact Information

Headquarters
1920 MCKINNEY AVENUE, 7TH FLOORDALLAS, TX, United States 75201
Phone
972-277-1136
Fax
302-655-5049

Executives

Independent Chairman of the Board
Donald Keyser
President, Chief Executive Officer, Director
Panna Sharma
Chief Financial Officer, Secretary
David Margrave
Chief Scientific Officer
Kishor Bhatia
Chief Medical Officer
Marc Chamberlain

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$35.3M
Revenue (TTM)
$0.00
Shares Outstanding
10.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.56
EPS
$-1.65
Book Value
$3.82
P/E Ratio
-2.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.